RecruitingPhase 2ACTRN12611000888965

Avastin versus Triamcinolone for Diabetic Macular Edema at the time of Cataract Surgery

Randomised, double-masked, controlled trial of intravitreal Avastin (bevacizumab) versus Triesence (triamcinolone) at the time of cataract surgery on the visual outcomes for patients with diabetic macular oedema


Sponsor

Royal Victorian Eye and Ear Hospital

Enrollment

100 participants

Start Date

Feb 29, 2012

Study Type

Interventional

Conditions

Summary

This study will compare two medications (Avastin (bevacizumab) and Triesence (Triamcinolone) given at the time of cataract surgery for patients with, or at high risk of developing, diabetic macular oedema. Patients will be seen monthly and outcomes include visual acuity, centra macular thickenss, time to retreatment and assesment of adverse events.


Eligibility

Sex: Both males and femalesMin Age: 19 Yearss

Inclusion Criteria2

  • Clinically significant macular oedema involving the fovea of the study eye at baseline OR which has occured within 24 months of study entry OR microaneurysms within the foveal avascular zone which are not amenable to treatment with laser
  • Cataract in the study eye which requires extraction in the opinion of the investigator

Exclusion Criteria11

  • Glaucoma with visual field defects or uncontrolled glaucoma
  • Past history of intraocular pressure rise >35mmHg following steroid treatment
  • Significant macular ischemia
  • Visual acuity of <6/60 in the fellow eye
  • Known allergies to the study medications
  • Systemic treatment with steroids >5mg prednisolone (or equivalent) daily
  • Intercurrent severe systemic disease or ocular infection
  • Women of childbearing potential not using adequate contraception or women who are breastfeeding
  • Intravitreal triamcinolone within 10 weeks of study entry
  • Intravitreal Avastin within 3 weeks of study entry
  • Argon laser photocoagulation within 3 months prior to study entry

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Arm 1: Avastin (bevacizumab) 1.25mg intravitreal injection, single dose administered immediately following cataract surgery

Arm 1: Avastin (bevacizumab) 1.25mg intravitreal injection, single dose administered immediately following cataract surgery


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000888965


Related Trials